Latest Ratios: P/E Ratio -4.8x · EV/EBITDA N/A · ROE -65.3%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $330M | $485M | $163M | $176M | $96M | $364M | $1.2B | $727M | $679M | $1.0B | $607M |
| Enterprise Value | $387M | $542M | $111M | $124M | $82M | $279M | $1.0B | $413M | $228M | $743M | $318M |
| P/E Ratio → | -4.84 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.53 | 6.65 | 3.93 | 232.58 | 4.99 | 11.99 | 22.53 | 47.83 | 53.33 | 41.30 | 14.25 |
| P/B Ratio | 4.35 | 6.39 | 1.24 | 2.07 | 0.76 | 1.54 | 3.72 | 2.04 | 1.51 | 3.64 | 2.21 |
| P/FCF | — | — | 8.35 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 7.38 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.43 | 2.68 | 164.17 | 4.26 | 9.20 | 19.89 | 27.21 | 17.94 | 29.52 | 7.47 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 5.70 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.6% | 86.6% | 77.9% | -882.6% | 55.7% | 93.9% | 96.2% | 25.0% | 78.5% | 89.6% | 96.0% |
| Operating Margin | -45.3% | -45.3% | -143.5% | -12887.7% | -467.7% | -341.0% | -82.9% | -813.4% | -825.5% | -367.8% | -150.2% |
| Net Profit Margin | -92.7% | -92.7% | -88.6% | -13385.3% | -553.6% | -376.3% | -158.8% | -672.1% | -618.1% | -394.5% | -150.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -65.3% | -65.3% | -34.1% | -96.0% | -58.6% | -41.9% | -24.4% | -25.3% | -21.4% | -35.5% | -22.7% |
| ROA | -19.1% | -19.1% | -10.2% | -33.9% | -33.0% | -26.8% | -17.3% | -21.1% | -18.9% | -29.9% | -18.2% |
| ROIC | -23.5% | -23.5% | -79.6% | -100.7% | -51.0% | -47.6% | -29.3% | -442.3% | — | — | — |
| ROCE | -16.7% | -16.7% | -30.0% | -51.6% | -33.8% | -27.6% | -10.3% | -28.8% | -28.3% | -32.9% | -22.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.58 | 1.58 | 0.70 | 1.00 | 0.60 | 0.43 | 0.35 | 0.13 | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.74 | -0.40 | -0.61 | -0.11 | -0.36 | -0.44 | -0.88 | -1.00 | -1.04 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -2.65 | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.39 | -7.39 | -3.93 | -20.95 | -25.04 | -21.20 | -14.01 | -38.05 | -122.11 | -185.14 | -10656.70 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.62 | 1.62 | 1.73 | 1.50 | 2.28 | 4.57 | 6.06 | 6.25 | 10.40 | 7.42 | 5.56 |
| Quick Ratio | 1.62 | 1.62 | 1.73 | 1.50 | 2.28 | 4.57 | 6.03 | 6.21 | 10.40 | 7.42 | 5.56 |
| Cash Ratio | 1.43 | 1.43 | 1.57 | 1.31 | 1.55 | 3.77 | 5.16 | 5.76 | 9.64 | 6.82 | 5.18 |
| Asset Turnover | — | 0.22 | 0.11 | 0.00 | 0.07 | 0.08 | 0.11 | 0.03 | 0.03 | 0.08 | 0.13 |
| Inventory Turnover | — | — | — | — | — | — | 1.21 | 3.93 | 9.96 | 10.48 | 14.33 |
| Days Sales Outstanding | — | 111.07 | 202.59 | 11182.05 | 334.59 | 373.74 | 137.22 | 367.48 | 632.66 | 66.15 | 31.09 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 12.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $100M | $91M | $57M | $46M | $45M | $43M | $42M | $41M | $36M | $36M |
Clinical Milestone Funding Dependency
Based on current market data, Cellectis trades at a price-to-sales multiple of 3.90, a figure that appears to reflect investor optimism regarding the AstraZeneca partnership rather than the company's underlying, non-recurring revenue stream or its persistent inability to generate positive earnings per share.
The lack of a meaningful P/E ratio or positive EBITDA highlights that valuation is driven entirely by the perceived probability of future clinical success rather than current fundamental performance. Investors should monitor whether this premium holds as the company continues to burn cash, as any delay in milestone achievement may lead to a significant contraction in valuation multiples relative to peers.
As reported in recent financial statements, Cellectis's ROIC has remained consistently negative, bottoming out at -35.4% in 2023Q4, which underscores the company's ongoing struggle to generate a return on the capital invested into its proprietary TALEN gene-editing platform and associated manufacturing infrastructure.
The persistent decay in returns on invested capital suggests that the company's R&D spending is not yet translating into value-accretive clinical assets. Without a transition to a commercial-stage model, the company will likely continue to destroy shareholder value, as the cost of capital remains high relative to the company's ability to monetize its intellectual property.
According to historical data, the company's asset turnover ratio has languished at 0.02 to 0.03 in recent quarters, indicating that the firm's asset base is currently underutilized and failing to generate sufficient revenue to offset the high fixed costs of its specialized manufacturing facilities.
The extremely high days sales outstanding and days payable outstanding figures suggest significant friction in the company's cash conversion cycle, likely exacerbated by the lumpy nature of milestone-based partnership payments. This inefficiency warrants further investigation, as it complicates the company's ability to manage its liquidity during periods of low milestone activity.
Based on the latest quarterly filings, the company's debt-to-equity ratio has climbed to 1.81 as of 2026Q1, signaling an increasing reliance on debt financing to bridge the gap between high R&D burn and the company's lumpy, milestone-dependent revenue inflows.
The negative interest coverage ratio of -11.95 indicates that the company is currently unable to service its debt obligations through operating income alone. This trend suggests that the company's balance sheet is becoming increasingly vulnerable, and investors should monitor the potential for further equity dilution as a necessary step to manage this rising leverage.
The most commonly misapplied metric for Cellectis is the price-to-sales ratio, which obscures the fact that the company's revenue is derived from non-recurring milestone payments rather than sustainable, volume-driven commercial sales, thereby providing a misleading impression of the company's underlying financial health.
Analysts should instead focus on the cash burn rate and the remaining cash runway, as these metrics provide a more accurate assessment of the company's survival risk. Relying on revenue multiples in a pre-commercial biotech context may lead to an overestimation of the company's stability, as it ignores the high probability of future capital raises.
Includes 30+ ratios · 19 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLLS stock.
Cellectis S.A.'s current P/E ratio is -4.8x. This places it at the 50th percentile of its historical range.
Cellectis S.A.'s return on equity (ROE) is -65.3%. The historical average is -41.3%.
Based on historical data, Cellectis S.A. is trading at a P/E of -4.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cellectis S.A. has 86.6% gross margin and -45.3% operating margin.